Neuroprotection peptides

19 peptides tagged neuroprotection. Each page carries the dosing reference, mechanism, evidence grade and references.

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

  • 9-Me-BC

    9-Methyl-beta-carboline, a small-molecule alkaloid shown in rodent studies to promote dopamine neuron survival and improve learning and memory.

    Evidence: Preclinical

  • Adamax

    Adamantane-modified analog of the ACTH(4-7) peptide Semax, intended for greater lipophilicity and brain uptake; almost no published research exists.

    Evidence: Anecdotal

  • ARA-290

    Synthetic 11-amino-acid peptide derived from the helix-B region of erythropoietin that activates the innate repair receptor without EPO's blood-cell effects.

    Evidence: Clinical

  • Cerebrolysin

    Porcine brain-derived mixture of low-molecular-weight neuropeptides and free amino acids with neurotrophic activity; trialled in humans for stroke and dementia.

    Evidence: Clinical

  • Cortagen

    Khavinson-series synthetic tetrapeptide (AEDP) designed from the brain extract Cortexin; studied in rats for sciatic nerve regeneration and in rodent brain for antioxidant effects.

    Evidence: Preclinical

  • Dihexa

    Angiotensin IV-derived peptide analog; rodent studies report memory rescue in some models, but the founding papers for its HGF/c-Met mechanism were retracted in 2025.

    Evidence: Preclinical

  • FGL-S

    Peptide mimetic of neural cell adhesion molecule (NCAM) defined in patent filings; one published study tested it in rats and monkeys, and the memory literature belongs to its parent FGL.

    Evidence: Anecdotal

  • Humanin

    24-amino-acid peptide encoded within mitochondrial DNA that protected neurons and other cells from oxidative and apoptotic stress in animal and cell studies.

    Evidence: Preclinical

  • Methylene Blue

    Phenothiazine redox dye (not a peptide) that can act as an alternative electron carrier in mitochondria; low oral doses studied in humans for memory and cerebral metabolism.

    Evidence: Clinical

  • N-Acetyl Selank Amidate

    Acetylated, amidated analog of Selank, a tuftsin-derived heptapeptide; Russian research on the parent peptide reports anxiolytic and mild nootropic effects without sedation.

    Evidence: Anecdotal

  • N-Acetyl Semax Amidate

    Acetylated, amidated analog of Semax, a synthetic ACTH(4-10) fragment; research on the parent peptide reports BDNF/NGF upregulation and neuroprotection in stroke models.

    Evidence: Anecdotal

  • Noopept

    Omberacetam, a synthetic dipeptide prodrug of cycloprolylglycine; Russian human and animal studies report memory benefits linked to BDNF and NGF upregulation.

    Evidence: Clinical

  • P21 (P021)

    P021, a CNTF-derived peptide (Ac-DGGL plus an adamantylated glycine, amide) that improved memory and neurogenesis in mouse and rat models of Alzheimer's disease and aging, given in the diet.

    Evidence: Preclinical

  • PE-22-28

    Truncated analog of the natriuretic-peptide-derived peptide spadin that blocks the TREK-1 potassium channel; studied in rodents for rapid antidepressant and neurogenic effects.

    Evidence: Preclinical

  • PHDP5

    Dodecapeptide from the dynamin 1 pleckstrin homology domain that blocks microtubule-dynamin binding; intranasal dosing rescued memory in Alzheimer-model mice. No human data.

    Evidence: Preclinical

  • Pinealon

    Khavinson-series synthetic tripeptide (EDR) from the brain drug Cortexin; protected neurons from oxidative stress in vitro and in rats, and preserved dendritic spines in Alzheimer model mice.

    Evidence: Preclinical

  • Selank

    Tuftsin-derived synthetic heptapeptide developed in Russia; small human trials report anxiolytic and mild nootropic effects without sedation or dependence.

    Evidence: Clinical

  • Semax

    Synthetic ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia; studied intranasally for attention, memory, and BDNF-linked neuroprotection.

    Evidence: Clinical

  • VIP

    Vasoactive intestinal peptide, a 28-amino-acid neuropeptide acting at VPAC1 and VPAC2 receptors; studied for vasodilation, immune modulation and neuroprotection.

    Evidence: Clinical

Other categories